Metoclopramide Hcl Basi (Metoclopramide Hydrochloride Monohydrate)

The drug works by competitively blocking dopamine D2 receptors in the chemoreceptor trigger zone and throughout the gastrointestinal tract, while also antagonising serotonin 5‑HT3 receptors. This dual action enhances gastric motility and reduces the central perception of nausea and vomiting.

The appropriate dose of Metoclopramide is determined by the prescribing clinician based on the specific indication, patient age, weight, renal function and severity of symptoms. Typical adult regimens range from 10 mg to 20 mg administered intravenously or intramuscularly, but exact dosing must follow the prescriber’s order.

Safety data for Metoclopramide during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Metoclopramide differs from serotonin‑type antiemetics such as ondansetron by targeting dopamine D2 receptors in addition to 5‑HT3 receptors. This gives it pro‑kinetic properties useful for gastroparesis, whereas ondansetron lacks gastric motility effects. Choice of therapy depends on the clinical scenario, patient tolerance and potential side‑effect profiles.

Metoclopramide injectable solution should be stored at ambient temperature, away from direct sunlight, and kept in its original packaging to protect from moisture. Do not freeze the product, and ensure that vials are inspected for particulate matter before administration.

The medication is supplied as an injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, typically using aseptic technique, and the injection site or infusion rate is selected according to the prescribed dose and clinical indication.

Serious adverse reactions include tardive dyskinesia, a potentially irreversible movement disorder, neuroleptic malignant syndrome, severe depression or suicidal ideation, seizures, and anaphylactic reactions. Patients should be monitored closely for any signs of these conditions, especially with prolonged therapy.

Metoclopramide is contraindicated in patients with known hypersensitivity to the drug, those with a history of tardive dyskinesia, and individuals taking monoamine oxidase inhibitors (MAOIs) within 14 days. Caution is also advised for patients with gastrointestinal obstruction, perforation, or severe renal impairment.